[1] Randall WY et al. Consensus Guidelines for Therapeutic Drug Monitoring of Rapamycin: Report of the Consensus Panel, Ther Drug Monit 1995; 17:676–680
[2] Morris RG, Cyclosporin Therapeutic Drug Monitoring – an Established Service Revisited, Clin Biochem Rev 2003; 24:33–46
[3] Wallemacq P et al. Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference, Ther Drug Monit 2009; 31:139–152
[4] Shipkova M et al. Therapeutic Drug Monitoring of Everolimus: A Consensus Report, Ther Drug Monit 2016; 38:143–169
[5] Shipkova M et al. Multi-center analytical evaluation of a novel automated tacrolimus immunoassay, Clin Biochem 2014; 47:1069–1077
[6] Grote-Koska D et al. Performance of the New RapidFire System for Therapeutic Monitoring of Immunosuppressants, Ther Drug Monit 2015; 37:400–404
[7] Taylor PJ. Matrix effects: The Achilles heel of quantitative high-performance liquid chromatography–electrospray–tandem mass spectrometry, Clin Biochem 2005; 38:328–334
[8] Heideloff C et al. Comparison of a stable isotope-labeled and an analog internal standard for the quantification of everolimus by a liquid chromatography-tandem mass spectrometry method, Ther Drug Monit 2013; 35:246–250
[9] Levine DM et al. The Need for Standardization of Tacrolimus Assays, Clin Chem 2011; 57:1739–1747
[10] Grote-Koska D et al. A candidate reference measurement procedure for Cyclosporine A in whole blood, Accred Qual Assur 2014; 19:147–15